Literature DB >> 23911788

JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells.

Arata Nishimoto1, Naruji Kugimiya, Toru Hosoyama, Tadahiko Enoki, Tao-Sheng Li, Kimikazu Hamano.   

Abstract

Recent studies have revealed that unphosphorylated STAT3 forms a dimer, translocates to the nucleus, binds to the STAT3 binding site, and activates the transcription of STAT3 target genes, thereby playing an important role in oncogenesis in addition to phosphorylated STAT3. Among signaling steps of unphosphorylated STAT3, nuclear translocation and target DNA-binding are the critical steps for its activation. Therefore, elucidating the regulatory mechanism of these signaling steps of unphosphorylated STAT3 is a potential step in the discovery of a novel cancer drug. However, the mechanism of unphosphorylated STAT3 binding to the promoter of target genes remains unclear. In this study, we focused on Jun activation domain-binding protein 1 (JAB1) as a candidate protein that regulates unphosphorylated STAT3 DNA-binding activity. Initially, we observed that both unphosphorylated STAT3 and JAB1 existed in the nucleus of human colon cancer cell line COLO205 at the basal state (no cytokine stimulation). On the other hand, phosphorylated STAT3 did not exist in the nucleus of COLO205 cells at the basal state. Immunoprecipitation using nuclear extract of COLO205 cells revealed that JAB1 interacted with unphosphorylated STAT3. To investigate the effect of JAB1 on unphosphorylated STAT3 activity, RNAi studies were performed. Although JAB1 knockdown tended to increase nuclear STAT3 expression, it significantly decreased unphosphorylated STAT3 DNA-binding activity. Subsequently, JAB1 knockdown significantly decreased the expression levels of MDR1, NANOG, and VEGF, which are STAT3 target genes. Furthermore, the expression level of nuclear JAB1, but not nuclear STAT3, correlated with unphosphorylated STAT3 DNA-binding activity between COLO205 and LoVo cells. Taken together, these results suggest that nuclear JAB1 positively regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cell line COLO205.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  JAB1; Protein–protein interaction; STAT3 DNA-binding activity; Unphosphorylated STAT3

Mesh:

Substances:

Year:  2013        PMID: 23911788     DOI: 10.1016/j.bbrc.2013.07.105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Reverse correlation of Jab1 and Smad4 in PANC-1 cells involved in the pathogenesis of pancreatic cancer.

Authors:  Jun Li; Zhuoyu Gu; Siyuan Li; Zhiwei Xiao; Kan Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.

Authors:  Naruji Kugimiya; Arata Nishimoto; Tohru Hosoyama; Koji Ueno; Yoshihiro Takemoto; Eijiro Harada; Tadahiko Enoki; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

3.  The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.

Authors:  Naruji Kugimiya; Arata Nishimoto; Tohru Hosoyama; Koji Ueno; Tadahiko Enoki; Tao-Sheng Li; Kimikazu Hamano
Journal:  J Cell Mol Med       Date:  2015-02-17       Impact factor: 5.310

4.  Hepatitis B virus promotes cancer cell migration by downregulating miR-340-5p expression to induce STAT3 overexpression.

Authors:  Qiushuang Xiong; Shaoshuai Wu; Jingwen Wang; Xianhuang Zeng; Jianwen Chen; Mingcong Wei; Haotong Guan; Chengpeng Fan; Lang Chen; Deyin Guo; Guihong Sun
Journal:  Cell Biosci       Date:  2017-04-12       Impact factor: 7.133

Review 5.  Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.

Authors:  Guohong Liu; Francois X Claret; Fuling Zhou; Yunbao Pan
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

Review 6.  STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment.

Authors:  Federica Laudisi; Fabio Cherubini; Giovanni Monteleone; Carmine Stolfi
Journal:  Int J Mol Sci       Date:  2018-06-16       Impact factor: 5.923

Review 7.  Ailanthone: A novel potential drug for treating human cancer.

Authors:  Haixiang Ding; Xiuchong Yu; Chen Hang; Kaijun Gao; Xifeng Lao; Yangtao Jia; Zhilong Yan
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

Review 8.  Nucleus, Mitochondrion, or Reticulum? STAT3 à La Carte.

Authors:  Lidia Avalle; Valeria Poli
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

Review 9.  Multiple regulation pathways and pivotal biological functions of STAT3 in cancer.

Authors:  Jie Yuan; Fei Zhang; Ruifang Niu
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

10.  Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma.

Authors:  Qi Shen; Bin Shang; Bin Jiang; Yu Wang; Zhou Wang; Gang Chen
Journal:  Thorac Cancer       Date:  2020-02-16       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.